Direkt zum Inhalt
Merck
  • Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): typical clinical and neuroimaging features in a Brazilian family.

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): typical clinical and neuroimaging features in a Brazilian family.

Arquivos de neuro-psiquiatria (2011-06-01)
José Luiz Pedroso, Pedro Braga-Neto, Agessandro Abrahão, René Leandro Magalhães Rivero, Carolina Abdalla, Nitamar Abdala, Orlando Graziani Povoas Barsottini
ZUSAMMENFASSUNG

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disorder characterized by late-infantile onset spastic ataxia and other neurological features. ARSACS has a high prevalence in northeastern Quebec, Canada. Several ARSACS cases have been reported outside Canada in recent decades. This is the first report of typical clinical and neuroimaging features in a Brazilian family with probable diagnosis of ARSACS.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Cyclobenzaprine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Cyclobenzaprin -hydrochlorid
Cyclobenzaprin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard